| Gefitinib |
| N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine |
| (CAS 184475-35-2) |
 |
| Description： |
Overactivity of the epidermal growth factor receptor-associated tyrosine kinase (EGFR-TK) has been associated with a number of cancers and thus TK inhibitors could be potential therapeutic agents to prevent malignant growth. Gefitinib is a selective EGFR-TK inhibitor that blocks the growth of GEO colon cancer, ZR-75-1 and MCF-10A Ha-ras breast cancer, and OVCAR-3 ovarian cancer cell lines with IC50s ranging between 0.2-0.4 µM. By interfering with the intracellular kinase domain, gefitinib prevents EGFR autophosphorylation and prevents downstream signal transduction. Gefitinib has been used to treat advanced (or recurrent) non-small cell lung cancer. However, the FDA retracted its general approval for this compound (Iressa™) when a phase III trial failed to demonstrate an overall survival benefit. Gefitinib appears to be most efficacious in treating certain EGFR gene mutations that are prevalent in Asian populations. |
| Product No. |
KT20006 |
| Product Name |
Gefitinib |
| Synonyms |
Iressa; ZD 1839; ZD-1839; ZD1839 |
| Formal Name |
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine |
| CAS Number |
184475-35-2 |
| Molecular Formula |
C22H24ClFN4O3 |
| Formula Weight |
446.9 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
1 year |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
AEE788
Afatinib
Afatinib dimaleate
AG 18
AG-1478
Bosutinib
Erlotinib
Lapatinib |
|
